RS61901B1 - Neutralizacija inhibitornih puteva u limfocitima - Google Patents

Neutralizacija inhibitornih puteva u limfocitima

Info

Publication number
RS61901B1
RS61901B1 RS20210534A RSP20210534A RS61901B1 RS 61901 B1 RS61901 B1 RS 61901B1 RS 20210534 A RS20210534 A RS 20210534A RS P20210534 A RSP20210534 A RS P20210534A RS 61901 B1 RS61901 B1 RS 61901B1
Authority
RS
Serbia
Prior art keywords
lymphocytes
neutralization
inhibitory pathways
pathways
inhibitory
Prior art date
Application number
RS20210534A
Other languages
English (en)
Inventor
Pascale Andre
Mathieu Blery
Caroline Denis
Carine Paturel
Nicolai Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS61901(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of RS61901B1 publication Critical patent/RS61901B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RS20210534A 2016-01-21 2017-01-20 Neutralizacija inhibitornih puteva u limfocitima RS61901B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281217P 2016-01-21 2016-01-21
EP17702315.7A EP3405495B1 (en) 2016-01-21 2017-01-20 Neutralization of inhibitory pathways in lymphocytes
PCT/EP2017/051153 WO2017125532A1 (en) 2016-01-21 2017-01-20 Neutralization of inhibitory pathways in lymphocytes

Publications (1)

Publication Number Publication Date
RS61901B1 true RS61901B1 (sr) 2021-06-30

Family

ID=57944387

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210534A RS61901B1 (sr) 2016-01-21 2017-01-20 Neutralizacija inhibitornih puteva u limfocitima

Country Status (21)

Country Link
US (3) US10870700B2 (sr)
EP (2) EP3405495B1 (sr)
JP (2) JP7301538B2 (sr)
KR (1) KR20180101549A (sr)
CN (2) CN108884163B (sr)
AU (2) AU2017208554B2 (sr)
CA (1) CA3012055A1 (sr)
CY (1) CY1124212T1 (sr)
DK (1) DK3405495T3 (sr)
ES (1) ES2871112T3 (sr)
HR (1) HRP20210778T1 (sr)
HU (1) HUE054356T2 (sr)
IL (1) IL260464B (sr)
LT (1) LT3405495T (sr)
PL (1) PL3405495T3 (sr)
PT (1) PT3405495T (sr)
RS (1) RS61901B1 (sr)
RU (1) RU2769569C2 (sr)
SG (2) SG11201805831RA (sr)
SI (1) SI3405495T1 (sr)
WO (1) WO2017125532A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US9512228B2 (en) 2011-06-17 2016-12-06 Novo Nordisk A/S Selective elimination of erosive cells
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SG11201701340RA (en) 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CA3092522A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
WO2019191764A1 (en) * 2018-03-28 2019-10-03 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
US20210253694A1 (en) * 2018-05-15 2021-08-19 Medimmune Limited Treatment of cancer
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
JP2022553927A (ja) * 2019-10-14 2022-12-27 イナート・ファルマ・ソシエテ・アノニム Ilt-2阻害剤での癌の処置
MX2023001776A (es) * 2020-08-12 2023-03-10 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
PT2476705E (pt) * 2004-12-28 2016-02-09 Innate Pharma Anticorpos monoclonais contra nkg2a
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー/エス 抗nkg2a抗体とその使用
MX2009014199A (es) 2007-06-18 2010-05-24 Organon Nv Anticuerpos para el receptor 1 de muerte programada pd-1 de humano.
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR101782570B1 (ko) 2008-12-09 2017-09-27 제넨테크, 인크. 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
AU2012245477C1 (en) 2011-04-20 2017-06-15 Medimmune, Llc Antibodies and other molecules that bind B7-H1 and PD-1
US9512228B2 (en) 2011-06-17 2016-12-06 Novo Nordisk A/S Selective elimination of erosive cells
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
KR20170051462A (ko) 2014-08-28 2017-05-11 아카데미슈 지켄후이스 라이덴 Cd94/nkg2a 및/또는 cd94/nkg2b 항체, 백신 조합물
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SG11201701340RA (en) * 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents

Also Published As

Publication number Publication date
CN116327916A (zh) 2023-06-27
JP2023134490A (ja) 2023-09-27
US20210122821A1 (en) 2021-04-29
CN108884163B (zh) 2022-08-16
CA3012055A1 (en) 2017-07-27
SG11201805831RA (en) 2018-08-30
EP3868787A1 (en) 2021-08-25
RU2769569C2 (ru) 2022-04-04
PT3405495T (pt) 2021-05-14
US10870700B2 (en) 2020-12-22
US20230303691A1 (en) 2023-09-28
PL3405495T3 (pl) 2021-10-11
IL260464B (en) 2022-02-01
CN108884163A (zh) 2018-11-23
SI3405495T1 (sl) 2021-08-31
EP3405495A1 (en) 2018-11-28
EP3405495B1 (en) 2021-02-24
AU2024202552A1 (en) 2024-05-16
HUE054356T2 (hu) 2021-09-28
JP2019506391A (ja) 2019-03-07
RU2018125490A (ru) 2020-02-21
LT3405495T (lt) 2021-08-10
RU2018125490A3 (sr) 2020-06-26
US20190031755A1 (en) 2019-01-31
DK3405495T3 (da) 2021-05-17
WO2017125532A1 (en) 2017-07-27
SG10202000645SA (en) 2020-03-30
JP7301538B2 (ja) 2023-07-03
HRP20210778T1 (hr) 2021-07-23
AU2017208554A1 (en) 2018-08-09
KR20180101549A (ko) 2018-09-12
ES2871112T3 (es) 2021-10-28
AU2017208554B2 (en) 2024-02-15
CY1124212T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
ZA201702642B (en) Neutralization of inhibitory pathways in lymphocytes
IL260464B (en) Neutralization of inhibition pathways in lymphocytes
IL256993B (en) bracket screws
IL288147A (en) ras inhibitory peptides and their uses
EP3316884A4 (en) THERAPEUTIC INHIBITING COMPOUNDS
IL260193A (en) Tlr inhibitory oligonucleotides and their use
PL3285606T3 (pl) Ochrona ciała
ZA201800413B (en) Dry suit
EP3414686A4 (en) AUTOMATIC DETECTION OF MALFUNCTION IN SURGICAL TOOLS
SG11201701717UA (en) Antiviral agents and uses thereof
HUE055790T2 (hu) Több töltõdarabú menetes rögzítõ
SG10201606767SA (en) Direct resistivity determination
DK3274600T3 (da) Gevindisætningsfejlhæmmende hanfastgørelseselement
SG11201710519PA (en) Evaluation of inhibitory circuit and use thereof
EP3387530C0 (en) SECURE COMPUTER
HK1209364A1 (en) Use of actinomyces naeslundii in the treatment or prevention of rheumatoid arthritis or related diseases
IL247732A0 (en) Perinase inhibitory peptides and their use in the treatment of clinical pathologies
AU5563P (en) Viclow Acmena smithii
GB201607978D0 (en) Inhibitory compounds
HK1209356A1 (en) Use of sutterella wadsworthensis in the treatment or prevention of rheumatoid arthritis or related diseases
GB201521152D0 (en) Dictionary/thesaurus
GB201517185D0 (en) Towel
GB201508876D0 (en) Sanitary protection
GB201509863D0 (en) Shower arrangement
GB201508203D0 (en) Water Ect